PE20001596A1 - Derivados de morfolina - Google Patents

Derivados de morfolina

Info

Publication number
PE20001596A1
PE20001596A1 PE2000000258A PE0002582000A PE20001596A1 PE 20001596 A1 PE20001596 A1 PE 20001596A1 PE 2000000258 A PE2000000258 A PE 2000000258A PE 0002582000 A PE0002582000 A PE 0002582000A PE 20001596 A1 PE20001596 A1 PE 20001596A1
Authority
PE
Peru
Prior art keywords
ilo
alkyl
ethyl
phenyl
cr4r5c
Prior art date
Application number
PE2000000258A
Other languages
English (en)
Inventor
Jean Philippe Ducoux
Vincenzo Proietto
Patrick Gueule
Xavier Emonds-Alt
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of PE20001596A1 publication Critical patent/PE20001596A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS DE MORFOLINA DE FORMULA I, DONDE: Ar ES FENILO SUSTITUIDO POR HALOGENO; ALQUILO C1-C3; X ES R2N, R3CH; R1 ES Cl, Br, ALQUILO C1-C3, TRIFLUOROMETILO; R2 ES ALQUILO C1-C6, CICLOALQUILO C3-C6, CR4R5C(O)NR6R7; R3 ES CR4R5C(O)NR6R7; R4 Y R5 SON METILO, ETILO, n-PROPLO, n-BUTILO; O JUNTO A C FORMAN UN CICLOALQUILO C3-C6; R6 Y R7 SON H, ALQUILO C1-C3 O JUNTO A N FORMAN UN HETEROCICLO COMO AZETIDIN-1-ILO, PIRROLIDIN-1-ILO, PIPERIDIN-1-ILO, MORFOLIN-4-ILO, TIOMORFOLIN-4-ILO, PERHIDROAZEPIN-1-ILO. SON COMPUETOS PREFERIDOS 2-[2-(4-CICLOHEXILPIPERAZIN-1-IL)ETIL]-2-(3,4-DICLOROFENIL)-4-[2-[3,5-BIS(TRIFLUOROMETIL)FENIL]ACETIL]MORFOLINA (ISOMERO +), 2-[2-[4-(1-CARBAMOILCICLOHEXIL)PIPERIDIN-1-IL]ETIL]-2-(3,4-DICLOROFENIL)-4-[2-[3,5-BIS-(TRIFLUOROMETIL)FENIL]ACETIL]MORFOLINA (ISOMERO +), ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION ; COMPUESTOS INTERMEDIOS; UNA COMPOSICION QUE COMPRENDE DE 0,1 mg A 1000 mg DE PRINCIPIO ACTIVO. EL COMPUESTO I IMPLICADOS CON LA SUSTANCIA P Y/O LOS RECEPTORES NK1 POR LO QUE PUEDE SER UTIL PARA EL TRATAMIENTO DE PATOLOGIAS DEL SISTEMA RESPIRATORIO, GASTROINTESTINAL, URINARIO, INMUNITARIO, CARDIOVASCULAR, MIGRANA, INFLAMACIONES
PE2000000258A 1999-03-25 2000-03-27 Derivados de morfolina PE20001596A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9903854A FR2791346B3 (fr) 1999-03-25 1999-03-25 Nouveaux derives de morpholine, procede pour leur preparation et compositions pharmaceutiques les contenant

Publications (1)

Publication Number Publication Date
PE20001596A1 true PE20001596A1 (es) 2001-04-01

Family

ID=9543720

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000258A PE20001596A1 (es) 1999-03-25 2000-03-27 Derivados de morfolina

Country Status (41)

Country Link
US (1) US6506750B1 (es)
EP (1) EP1165528B1 (es)
JP (1) JP3853155B2 (es)
KR (1) KR100696340B1 (es)
CN (1) CN100422160C (es)
AR (1) AR023139A1 (es)
AT (1) ATE275136T1 (es)
AU (1) AU756855B2 (es)
BG (1) BG64623B1 (es)
BR (1) BR0009281B1 (es)
CA (1) CA2366829C (es)
CO (1) CO5160340A1 (es)
CZ (1) CZ300911B6 (es)
DE (1) DE60013418T2 (es)
DK (1) DK1165528T3 (es)
EE (1) EE04525B1 (es)
ES (1) ES2226794T3 (es)
FR (1) FR2791346B3 (es)
HK (1) HK1042092B (es)
HR (1) HRP20010704B1 (es)
HU (1) HUP0201863A3 (es)
ID (1) ID29871A (es)
IL (2) IL145041A0 (es)
IS (1) IS2338B (es)
ME (2) MEP12008A (es)
MX (1) MXPA01009643A (es)
NO (1) NO321576B1 (es)
NZ (1) NZ513674A (es)
PE (1) PE20001596A1 (es)
PL (1) PL205318B1 (es)
PT (1) PT1165528E (es)
RS (1) RS50085B (es)
RU (1) RU2222537C2 (es)
SI (1) SI1165528T1 (es)
SK (1) SK286977B6 (es)
TR (1) TR200102639T2 (es)
TW (1) TW534906B (es)
UA (1) UA73931C2 (es)
UY (1) UY26079A1 (es)
WO (1) WO2000058292A1 (es)
ZA (1) ZA200106981B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1353918B1 (en) * 2000-11-28 2005-01-12 Smithkline Beecham Plc Morpholine derivatives as antagonists of orexin receptors
FR2824828B1 (fr) * 2001-05-21 2005-05-20 Sanofi Synthelabo Nouveaux derives de piperidinecarboxamide, un procede pour leur preparation et les compositions pharmaceutiques les contenant
GB0228787D0 (en) * 2002-12-10 2003-01-15 Pfizer Ltd Morpholine dopamine agonists
AU2003300911A1 (en) 2002-12-13 2004-07-09 Smithkline Beecham Corporation Heterocyclic compounds as ccr5 antagonists
JO2485B1 (en) * 2002-12-23 2009-01-20 شركة جانسين فارماسوتيكا ان. في 1-Piperidine-3-Yl-4-Piperidine-4-Yl-Piperazine derivatives substituted and used as quinine antagonists
JP2007515425A (ja) * 2003-12-22 2007-06-14 シェーリング コーポレイション 医薬組成物
FR2873373B1 (fr) * 2004-07-23 2006-09-08 Sanofi Synthelabo Derives de 4-arylmorpholin-3-one, leur preparation et leur application en therapeutique
CN103142569B (zh) * 2013-02-27 2016-01-20 南京医科大学 2,6-二异丙基苯甲酸及其衍生物作为神经保护剂的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ3134U1 (cs) * 1995-01-10 1995-03-17 Pavel Ing. Janda Rotor universálního radiálního ventilátoru
FR2729954B1 (fr) * 1995-01-30 1997-08-01 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
US5780466A (en) * 1995-01-30 1998-07-14 Sanofi Substituted heterocyclic compounds method of preparing them and pharmaceutical compositions in which they are present
HU224225B1 (hu) * 1995-12-01 2005-06-28 Sankyo Co. Ltd. Tachikinin receptor antagonista hatású heterociklusos vegyületek, ezek előállítási eljárása és alkalmazásuk gyógyszerkészítmények előállítására
JP3192631B2 (ja) * 1997-05-28 2001-07-30 三共株式会社 飽和複素環化合物からなる医薬
KR100610538B1 (ko) * 1997-12-04 2006-08-09 상꾜 가부시키가이샤 지환식 아실화 복소환 유도체

Also Published As

Publication number Publication date
HK1042092A1 (en) 2002-08-02
RS50085B (sr) 2009-01-22
IL145041A0 (en) 2002-06-30
HRP20010704A2 (en) 2002-08-31
WO2000058292A1 (fr) 2000-10-05
ZA200106981B (en) 2002-10-24
BR0009281B1 (pt) 2011-05-17
UA73931C2 (en) 2005-10-17
CA2366829C (fr) 2007-05-15
EE200100499A (et) 2002-12-16
NZ513674A (en) 2003-05-30
AR023139A1 (es) 2002-09-04
KR20010108381A (ko) 2001-12-07
TR200102639T2 (tr) 2002-02-21
EP1165528A1 (fr) 2002-01-02
KR100696340B1 (ko) 2007-03-20
HRP20010704B1 (en) 2005-04-30
DE60013418D1 (de) 2004-10-07
SK13462001A3 (sk) 2002-05-09
IS6063A (is) 2001-08-24
PL205318B1 (pl) 2010-04-30
EP1165528B1 (fr) 2004-09-01
CN100422160C (zh) 2008-10-01
PL351317A1 (en) 2003-04-07
MXPA01009643A (es) 2002-05-14
AU3301600A (en) 2000-10-16
BG105923A (en) 2002-05-31
HUP0201863A3 (en) 2003-03-28
YU68201A (sh) 2004-03-12
ME00057B (me) 2010-10-10
SI1165528T1 (en) 2005-02-28
FR2791346B3 (fr) 2001-04-27
CO5160340A1 (es) 2002-05-30
AU756855B2 (en) 2003-01-23
UY26079A1 (es) 2000-10-31
TW534906B (en) 2003-06-01
DK1165528T3 (da) 2005-01-10
SK286977B6 (sk) 2009-08-06
BR0009281A (pt) 2002-01-22
ES2226794T3 (es) 2005-04-01
IL145041A (en) 2010-11-30
FR2791346A1 (fr) 2000-09-29
HUP0201863A2 (hu) 2002-12-28
DE60013418T2 (de) 2005-09-22
BG64623B1 (bg) 2005-09-30
CN1353698A (zh) 2002-06-12
MEP12008A (en) 2010-06-10
EE04525B1 (et) 2005-08-15
CZ300911B6 (cs) 2009-09-09
NO321576B1 (no) 2006-06-06
ATE275136T1 (de) 2004-09-15
JP2002540195A (ja) 2002-11-26
ID29871A (id) 2001-10-18
JP3853155B2 (ja) 2006-12-06
HK1042092B (zh) 2005-04-22
CA2366829A1 (fr) 2000-10-05
NO20014632D0 (no) 2001-09-24
IS2338B (is) 2008-02-15
NO20014632L (no) 2001-11-26
US6506750B1 (en) 2003-01-14
RU2222537C2 (ru) 2004-01-27
CZ20013365A3 (cs) 2002-01-16
PT1165528E (pt) 2005-01-31

Similar Documents

Publication Publication Date Title
AR048642A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento
PE20060525A1 (es) Compuestos heterociclicos como inhibidores de cetp
PE20050874A1 (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4
PE20020506A1 (es) Derivados de pirazol fusionados como inhibidores de la proteina cinasa
PE20030702A1 (es) Inhibidores de pde9 para tratamiento de transtornos cardiovasculares
PE20011371A1 (es) Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
RU2011152891A (ru) Диарилгидантоины
ES2121441T3 (es) Nuevos derivados de 3,5 -dioxo - (2h,4h) - 1,2,4 - triazina,su preparacion y aplicacion como farmaco
PE20080730A1 (es) Derivados de fenilo como moduladores del receptor s1p
PE20051054A1 (es) Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento
DOP2003000703A (es) Compuestos de imidazopiradina como agonistas del receptor 5-ht4
CA2401502A1 (en) Carboxylic acid derivatives as ip antagonists
EA200601076A1 (ru) Применение производных n-арилгидразина для борьбы с вредителями
PE20011115A1 (es) Etanos tri-aril-sustituidos inhibidores de pde4
FI941644A0 (fi) Sieniä vastustavat triatsoliyhdisteet
PE20050587A1 (es) Derivados de diazindol-dicarbonilo-piperazinilo como agentes antivirales
AU2003269923A8 (en) 2- (phenoxymethyl)- and 2- (phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
JP2004525183A5 (es)
CL2009001146A1 (es) Compuestos derivados de 5-(5-(2-(3,5-bis(trifluorometil)fenil)-n,2-dimetilpropanoamida)-4-(4-fluoro-2-metilfenil)piridin-2-il)pirrolidin-2-carboxamida, antagonistas de los receptores nk-1; composicion farmaceutica; y uso del compuesto para el tratamiento de la depresion; ansiedad, trastornos del sueño o emesis.
DE60008218D1 (de) Heterozyklische verbindungen, ihre zwischenprodukte und elastase-inhibitoren
PE20120217A1 (es) Derivados de carbamatos de alquil-heterociclos, su preparacion y su aplicacion en terapeutica
DK1390036T3 (da) Prostansyrederivater som midler til nedsættelse af intraokulært tryk
PE20021018A1 (es) DERIVADOS DE ß - CARBOLINA
PE20020905A1 (es) Derivados de alcoxicarbonilaminotetrazolil fenilo o acido alcoxicarbonilamino benzoico como antagonistas ip
PE20060770A1 (es) Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed